Differential effects of dual antiplatelet and dual antithrombotic therapy on hemostasis in chronic coronary syndrome patients: the DEFINE CCS study

Differential effects of dual antiplatelet and dual antithrombotic therapy on hemostasis in chronic coronary syndrome patients: the DEFINE CCS study

Optimal long term antithrombotic treatment in high-risk chronic coronary syndrome (CCS) patients remains uncertain. Both ticagrelor (60 mg BID) and low-dose rivaroxaban (2.5 mg BID) in addition to low-dose aspirin resulted in significant reductions in major cardiovascular events in high-risk patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Tony Haddad, Osama Elkhateeb, Lawrence Title, Ata Quraishi, Wan Cheol Kim, Ali Hillani, Scott Grandy, Stefan S. Heinze, Finn Eichhorn, Hannah Harquail, John Sapp, William Parker, Shamir R. Mehta, Robert F. Storey, Wael Sumaya
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Platelets
Subjects:
Chronic coronary syndrome
haemostasis
rivaroxaban
ticagrelor
Online Access:https://www.tandfonline.com/doi/10.1080/09537104.2025.2524624
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09537104.2025.2524624

Similar Items